332 222

Cited 35 times in

Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy

Authors
 Steven H. Lin  ;  Thomas J. George  ;  Edgar Ben-Josef  ;  Jeffrey Bradley  ;  Kevin S. Choe  ;  Martin J. Edelman  ;  Chandan Guha  ;  Sunil Krishnan  ;  Theodore S. Lawrence  ;  Quynh-Thu Le  ;  Bo Lu  ;  Minesh Mehta  ;  David Peereboom  ;  Jann Sarkaria  ;  Jinsil Seong  ;  Dian Wang  ;  Meng X. Welliver  ;  C. Norman Coleman  ;  Bhadrasain Vikram  ;  Stephen Yoo  ;  Christine H. Chung 
Citation
 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol.105(10) : 686-693, 2013 
Journal Title
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
ISSN
 0027-8874 
Issue Date
2013
MeSH
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology* ; Biomarkers, Tumor/analysis* ; Brain Neoplasms/radiotherapy ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Clinical Trials, Phase I as Topic ; Congresses as Topic ; Cranial Irradiation ; Humans ; Kaplan-Meier Estimate ; Molecular Targeted Therapy/methods* ; National Cancer Institute (U.S.) ; Neoplasms/chemistry ; Neoplasms/drug therapy* ; Neoplasms/pathology ; Neoplasms/radiotherapy* ; Precision Medicine/trends* ; Radiation-Sensitizing Agents/therapeutic use ; Radiotherapy, Adjuvant ; Research Design ; Research Support as Topic ; Severity of Illness Index ; United States
Keywords
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology* ; Biomarkers, Tumor/analysis* ; Brain Neoplasms/radiotherapy ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Clinical Trials, Phase I as Topic ; Congresses as Topic ; Cranial Irradiation ; Humans ; Kaplan-Meier Estimate ; Molecular Targeted Therapy/methods* ; National Cancer Institute (U.S.) ; Neoplasms/chemistry ; Neoplasms/drug therapy* ; Neoplasms/pathology ; Neoplasms/radiotherapy* ; Precision Medicine/trends* ; Radiation-Sensitizing Agents/therapeutic use ; Radiotherapy, Adjuvant ; Research Design ; Research Support as Topic ; Severity of Illness Index ; United States
Abstract
The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.
Files in This Item:
T201305435.pdf Download
DOI
10.1093/jnci/djt055
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88998
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links